Neuland Laboratories (524558) Q2 24/25 earnings summary

Executive summary

• Q2 FY25 results were below recent quarters, reflecting the business's inherent volatility, but management remains focused on long-term growth through customer acquisition, capability expansion, and process optimization.

• Revenue in Q2 FY25 was driven by key molecules in the CMS and GDS specialty segments, with new manufacturing facilities and upcoming product launches expected to fuel high growth in FY26 and beyond.

• Unaudited financial results for the quarter and half year ended September 30, 2024, were approved by the Board on November 6, 2024.

Financial highlights

• Q2 FY25 total income was INR 315.2 crores, down from INR 422.8 crores in Q2 FY24, with EBITDA at INR 65.7 crores (20.8% margin) and PAT at INR 32 crores; EPS for the quarter was INR 24.9.

• H1 FY25 revenue was INR 759.6 crores, a 3.3% decline year-over-year; H1 EBITDA was INR 194.3 crores, down from INR 239.6 crores in H1 FY24.

• Free cash flow generated in H1 FY25 was INR 45.8 crores, with INR 17.1 crores used for debt repayment and INR 103.5 crores invested in capex.

• Exceptional profit of INR 20.6 crores from transfer of investment property in Q1 FY25.

• Working capital stands at 112 days of sales, with net debt position at negative INR 94.3 crores after repayments.

Outlook and guidance

• FY25 is expected to close flat compared to FY24, a revision from earlier moderate growth expectations, due to order timing and execution delays.

• High growth is anticipated from FY26 onward, driven by new facility completion and commercial launches in the CMS segment.

• Management remains cautiously optimistic, citing a strong order pipeline and favorable medium- to long-term industry trends.